ICUI Stock Overview
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy and critical care applications worldwide.
ICU Medical Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$208.69|
|52 Week High||US$282.00|
|52 Week Low||US$183.39|
|1 Month Change||-12.72%|
|3 Month Change||-9.36%|
|1 Year Change||2.62%|
|3 Year Change||-13.15%|
|5 Year Change||52.50%|
|Change since IPO||4,425.81%|
Recent News & Updates
Is Now The Time To Put ICU Medical (NASDAQ:ICUI) On Your Watchlist?
It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...
|ICUI||US Medical Equipment||US Market|
Return vs Industry: ICUI exceeded the US Medical Equipment industry which returned -3.7% over the past year.
Return vs Market: ICUI matched the US Market which returned 3.3% over the past year.
|ICUI Average Weekly Movement||3.1%|
|Medical Equipment Industry Average Movement||8.5%|
|Market Average Movement||6.7%|
|10% most volatile stocks in US Market||15.4%|
|10% least volatile stocks in US Market||2.4%|
Stable Share Price: ICUI is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: ICUI's weekly volatility (3%) has been stable over the past year.
About the Company
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy and critical care applications worldwide. The company’s infusion therapy products include needlefree connector products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; SwabCap disinfecting caps; Tego hemodialysis connectors; ClearGuard HD, an antimicrobial barrier cap for hemodialysis catheters; and ChemoLock and ChemoClave closed system transfer devices, as well as Diana hazardous drug compounding system for the preparation of hazardous drugs. It also provides IV therapy and diluents, including sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation, such as sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options.
ICU Medical Fundamentals Summary
|ICUI fundamental statistics|
Is ICUI overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ICUI income statement (TTM)|
|Cost of Revenue||US$812.36m|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||4.61|
|Net Profit Margin||8.44%|
How did ICUI perform over the long term?See historical performance and comparison
Is ICU Medical undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ICUI ($208.69) is trading below our estimate of fair value ($232.03)
Significantly Below Fair Value: ICUI is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: ICUI is poor value based on its PE Ratio (45.3x) compared to the US Medical Equipment industry average (45.1x).
PE vs Market: ICUI is poor value based on its PE Ratio (45.3x) compared to the US market (16.4x).
Price to Earnings Growth Ratio
PEG Ratio: ICUI is poor value based on its PEG Ratio (4.3x)
Price to Book Ratio
PB vs Industry: ICUI is good value based on its PB Ratio (3.1x) compared to the US Medical Equipment industry average (3.3x).
How is ICU Medical forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ICUI's forecast earnings growth (10.7% per year) is above the savings rate (2%).
Earnings vs Market: ICUI's earnings (10.7% per year) are forecast to grow slower than the US market (12.9% per year).
High Growth Earnings: ICUI's earnings are forecast to grow, but not significantly.
Revenue vs Market: ICUI's revenue (18.3% per year) is forecast to grow faster than the US market (9.1% per year).
High Growth Revenue: ICUI's revenue (18.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ICUI's Return on Equity is forecast to be low in 3 years time (7%).
How has ICU Medical performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ICUI has high quality earnings.
Growing Profit Margin: ICUI's current net profit margins (8.4%) are higher than last year (6.4%).
Past Earnings Growth Analysis
Earnings Trend: ICUI's earnings have grown by 13% per year over the past 5 years.
Accelerating Growth: ICUI's earnings growth over the past year (34.4%) exceeds its 5-year average (13% per year).
Earnings vs Industry: ICUI earnings growth over the past year (34.4%) underperformed the Medical Equipment industry 51.2%.
Return on Equity
High ROE: ICUI's Return on Equity (6.9%) is considered low.
How is ICU Medical's financial position?
Financial Position Analysis
Short Term Liabilities: ICUI's short term assets ($1.0B) exceed its short term liabilities ($185.1M).
Long Term Liabilities: ICUI's short term assets ($1.0B) exceed its long term liabilities ($64.3M).
Debt to Equity History and Analysis
Debt Level: ICUI is debt free.
Reducing Debt: ICUI had no debt 5 years ago.
Debt Coverage: ICUI has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: ICUI has no debt, therefore coverage of interest payments is not a concern.
What is ICU Medical current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ICUI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ICUI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ICUI's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ICUI's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ICUI's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Vivek Jain (49 yo)
Mr. Vivek Jain has been an Independent Director of Envista Holdings Corporation since April 7, 2020. Mr. Jain has been Chairman and Chief Executive Officer of ICU Medical, Inc. since February 13, 2014. Mr....
CEO Compensation Analysis
Compensation vs Market: Vivek's total compensation ($USD3.31M) is below average for companies of similar size in the US market ($USD6.49M).
Compensation vs Earnings: Vivek's compensation has been consistent with company performance over the past year.
Experienced Management: ICUI's management team is considered experienced (4 years average tenure).
Experienced Board: ICUI's board of directors are considered experienced (5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 13.1%.
ICU Medical, Inc.'s employee growth, exchange listings and data sources
- Name: ICU Medical, Inc.
- Ticker: ICUI
- Exchange: NasdaqGS
- Founded: 1984
- Industry: Health Care Supplies
- Sector: Healthcare
- Implied Market Cap: US$4.954b
- Shares outstanding: 23.74m
- Website: https://www.icumed.com
Number of Employees
- ICU Medical, Inc.
- 951 Calle Amanecer
- San Clemente
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/01/26 23:57|
|End of Day Share Price||2022/01/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.